← Back to Clinical Trials
Recruiting NCT07139860

NCT07139860 Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07139860
Status Recruiting
Phase
Sponsor Hui Chen
Condition Acute Myocardial Infarction With ST Elevation
Study Type OBSERVATIONAL
Enrollment 1,400 participants
Start Date 2022-11-26
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,400 participants in total. It began in 2022-11-26 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is: Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)? Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.

Eligibility Criteria

Inclusion Criteria: * 1\. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form. Exclusion Criteria: * 1\. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.

Contact & Investigator

Central Contact

Hui Chen

✉ 13910710028@163.com

📞 +86 13910710028

Frequently Asked Questions

Who can join the NCT07139860 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myocardial Infarction With ST Elevation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07139860 currently recruiting?

Yes, NCT07139860 is actively recruiting participants. Contact the research team at 13910710028@163.com for enrollment information.

Where is the NCT07139860 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07139860 clinical trial?

NCT07139860 is sponsored by Hui Chen. The trial plans to enroll 1,400 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology